Full-Time
Account Executive
Global Accounts
Cradle
51-200 employees
Generative AI platform for protein design
No salary listed
Company Does Not Provide H1B Sponsorship
East Coast of the United States, USA + 1 more
More locations: Boston, MA, USA
Hybrid
Hybrid work is listed for Boston and the U.S. East Coast; the role is based on the East Coast.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Cradle
See people who can refer or advise you
- An advanced degree in the life sciences, such as structural or molecular biology, bioinformatics, pharmaceutical sciences, or biochemical engineering, or equivalent hands-on experience working with research and development teams in biotechnology or pharmaceutical organizations.
- At least 5 years of business-to-business sales experience, ideally in software as a service, with a proven track record of consistently exceeding quota.
- Ability to navigate highly technical topics and translate them into business value for research and development stakeholders and executives.
- Ability to operate effectively in fast-paced, ambiguous environments and build sales processes from scratch.
- Ability to listen intently, demonstrate curiosity, and learn with humility.
- Drive business development across the global biotechnology and biopharmaceutical landscape by nurturing leads, identifying opportunities, and closing high-value enterprise deals.
- Own strategic accounts, focusing on large global players including the top 10 pharmaceutical companies, and deliver millions in annual recurring revenue.
- Partner cross-functionally with product, machine learning, engineering, and customer success teams to shape proposals and execute technically complex projects.
- Act as the voice of the market by surfacing customer feedback and strategic insights to inform product direction and roadmap priorities.
- Build a personal brand in the biotechnology and artificial intelligence-for-science space by attending global events, engaging with scientists and executives, and establishing trusted-advisor relationships.
- Improve sales playbooks, processes, and materials as the enterprise sales organization scales.
- A strong business network across biotechnology and pharmaceutical organizations on the U.S. East Coast.
- Domain knowledge in machine learning or its applications in life sciences.
- Prior experience at a business-to-business growth-stage startup.
- Prior experience working as a bioinformatician or wet-lab scientist in an industrial or academic setting.
Cradle Bio B.V. provides a subscription-based software platform that uses generative AI to accelerate protein engineering. Scientists upload a protein sequence, define goals like stability or binding, and the system generates and predicts many variants, with experimental validation feeding back to refine the model. Cradle also operates a wet lab to validate results and continuously improve its AI with proprietary data, enabling an end-to-end design-to-validation loop. Its goal is to speed up protein R&D timelines by 2–12x and scale the platform globally across life sciences, while customers retain full IP ownership without royalties.
Company Size
51-200
Company Stage
Series B
Total Funding
$103.1M
Headquarters
Amsterdam, Netherlands
Founded
2021
Get referred to Cradle
See people who can refer or advise you
Simplify's Take
What believers are saying
- Bayer signed a three-year collaboration on January 7, 2026 for antibody discovery.
- Lundbeck launched Cradle's first end-to-end AI-guided protein engineering workflow on June 3, 2026.
- Marcus Schindler joined Cradle's advisory board on March 3, 2026, strengthening pharma credibility.
What critics are saying
- Cradle sells subscriptions and no royalty rights, so customers can internalize value after adoption.
- Bayer and Lundbeck can pressure pricing by running parallel internal teams within twelve months.
- If generative protein design stagnates, OpenAI-style model commoditization crushes Cradle's software margin.
What makes Cradle unique
- Cradle runs a lab-in-the-loop SaaS platform from Amsterdam and Zurich, not a pure model layer.
- Its own wet lab continuously retrains protein models with proprietary experimental data.
- By June 2026, Cradle served eight top-25 pharma companies across 50-plus programs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Company Equity
Professional Development Budget
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↓ -4%Exclusive: A David Baker spinout launches AI antibody data consortium with GSK, Boltz and others. July 28, 2026 WOBN news, syndication comments off on exclusive: A David Baker spinout launches AI antibody data consortium with GSK, Boltz and others. A-Alpha Bio, a startup spun out of David Baker's lab, led by David Younger, has launched a first-of-its-kind AI antibody data consortium with GSK, Boltz Bio, Dyno Therapeutics, and Cradle. The initiative aims to accelerate AI-driven antibody discovery by generating and sharing large-scale experimental data among members.
Lundbeck partners with Cradle to discover and optimize brain disorder treatments. Cision Publicerad: Idag 14:00 Collaboration's initial focus will focus on two antibody programs targeting CNS diseases VALBY, Denmark & AMSTERDAM, 03 June 2026 - H. Lundbeck A/S (Lundbeck), a global biopharmaceutical company focused exclusively on brain health, and Cradle, a leading AI platform for protein engineering, today announced a partnership to help Lundbeck discover and optimize biotherapeutics that ultimately can improve patient outcomes. It is estimated that more than half of the world's population is impacted by brain disorders, and the effects are felt throughout society. Speeding up innovation time to develop high-quality biologics is a critical part of bringing effective new treatments to patients. As part of its aim to ease this burden and bring new treatments to patients in need, Lundbeck is deploying Cradle's AI-powered protein design platform to develop multiple higher-performing candidates that can accelerate breakthroughs for neurological conditions. "Lundbeck is committed to becoming a bionic company, embedding AI into how we work to complement human expertise and bring faster results," said Tarek Samad, SVP, Global Head of Research and Corporate Patents at Lundbeck. "Our partnership with Cradle fits perfectly with this commitment as their platform provides our scientists with powerful AI that fits seamlessly into our processes, strengthening our ability to discover and optimize therapeutics." The partnership is powering Lundbeck's first end-to-end AI-guided protein engineering workflow, where experimental results are continuously fed back into the model, enabling each iteration to improve prediction accuracy and accelerate convergence toward viable candidates. The platform will initially be used to advance two antibody programs targeting CNS diseases. Lundbeck's protein engineers and computational biologists will use Cradle's generative AI platform to engineer higher-quality antibody candidates while reducing the number of wet-lab iterations required to reach lead candidates. "Lundbeck has a strong biotherapeutic pipeline in CNS and is now strengthening that position with the power of AI across their research and development organization," said Stef van Grieken, CEO and Co-Founder of Cradle. "The Cradle platform has been shown in internal and partner programs to accelerate design cycles significantly. By closing the loop between computation and the lab, we can help Lundbeck reach high-quality antibody candidates faster and with fewer iterations." The Cradle partnership builds on Lundbeck's systematic embrace of AI to accelerate its Focused Innovator strategy. It complements a recently announced partnership with the Danish Centre for AI Innovation, which provides Lundbeck access to Denmark's Gefion AI supercomputer with advanced AI computing power for large-scale scientific modelling and discovery. Together, the two partnerships will strengthen Lundbeck's end-to-end AI discovery capabilities, from expanding the scientific search space to improving and accelerating specific biologic candidates. Across the organization, Lundbeck estimates AI-driven initiatives are already contributing more than 12,000 hours saved per week through efficiency gains. In drug discovery specifically, AI-enabled structural insights and predictions that once took months can now be generated in under 24 hours, while expanding the searchable scientific space by approximately 50,000x. About H. Lundbeck A/S. Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, Borskollen is committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, Borskollen hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, Borskollen strive for its research and development programs to tackle some of the most complex neurological challenges. Borskollen develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from its strong legacy within psychiatry and neurology. Borskollen is committed to fighting stigma and Borskollen act to improve health equity. Borskollen strive to create long term value for its shareholders by making a positive contribution to patients, their families and society as a whole. Lundbeck has more than 5,000 employees in more than 20 countries and its products are available in more than 80 countries. For additional information, Borskollen encourage you to visit its corporate site www.lundbeck.com and connect with Borskollen via LinkedIn. Contacts. | Anders Crillesen | Jens Høyer | | Senior Director, Corp. Communication | Vice President, Head of Investor Relations | | [email protected] | [email protected] | | +45 27 79 12 86 | +45 30 83 45 01 | | / | / | About cradle. Cradle's mission is to make engineering biology easier, quicker and more cost-effective. Its enterprise-grade AI software platform currently serves eight out of the top 25 global pharma companies, and is used across over 50 R&D programs. With Cradle, scientists can engineer better proteins, faster and more successfully, speeding up the development cycle of new therapeutics and bio-based products such as, antibodies, enzymes, and bio-based materials by 2-12x. Cradle is based in Amsterdam, The Netherlands; Zurich, Switzerland and the United States with a team of machine learning and biotech research specialists with experience at many of the world's leading technology and biotech companies, including Google, Novartis, Meta, Zymergen, Uber, Deepmind and Generate Biomedicines. Cradle is backed by IVP as well as Index Ventures and Kindred Capital. For more information, visit cradle.bio.
Cradle, an enterprise-grade AI platform for protein engineering, has appointed Marcus Schindler to its advisory board. Schindler previously served as executive vice president for research and early development and chief scientific officer at Novo Nordisk, where he oversaw pipeline development across multiple therapeutic areas. The Amsterdam and Zurich-based company now powers more than 50 protein R&D programmes globally and partners with six of the top 25 biopharma organisations, including Johnson & Johnson, AbbVie and Novo Nordisk. In 2026, Cradle announced a new partnership with Bayer for antibody discovery. Cradle's SaaS platform enables scientists to engineer proteins for various modalities including enzymes, peptides, vaccines and antibodies, accelerating early research and development by two to 12 times. The company is backed by IVP, Index Ventures and Kindred Capital.
Bayer partners with Cradle to advance ai-led drug discovery. Pharma giant Bayer has signed a three-year strategic collaboration with biotech company Cradle to advance AI-enabled antibody discovery and optimisation. Bayer aims to implement Cradle's AI software platform, used for protein engineering, to scale its drug discovery and development efforts. The company intends to integrate Cradle's platform with existing R&D workflows to enhance lead generation and optimisation across the therapeutic antibody pipeline. "We believe AI-driven molecule design, discovery and optimisation will be a key accelerator of our productivity moving forward," said Anastasia Hager, Global Head of Drug Discovery Sciences at Bayer's Pharmaceuticals Division. "Cradle's platform provides us with scalable scientist-centric solutions to maximise the opportunities in our biologics portfolio and potentially deliver faster, more effective medicines to patients." "Bayer's decision reflects a broader shift we're seeing: leading drug discovery organisations want AI that scales across portfolios, formats, and teams without requiring every scientist to become an ML expert or limiting AI's impact to asset-based deals," added Stef van Grieken, Co-Founder and CEO of Cradle. "Cradle brings enterprise-grade, lab-in-the-loop AI into the hands of the expert scientists working daily to design new molecules and treat diseases, helping reduce iterations while improving potency, developability, and manufacturability. We're excited to work with Bayer to operationalise AI at scale and translate it into faster, higher-quality candidates for the clinic." Under the agreement, Cradle will provide Bayer's antibody scientists with full access to its scientific AI software platform supporting a lab-in-the-loop approach, streamlined design-test-learn cycles, and coordinated execution across laboratory and external partners. Bayer and Cradle will also jointly work on a machine learning research project aimed at extending these capabilities even further.
In the ever-evolving world of startups and innovation, the Netherlands continues to shine as a breeding ground for young tech talent.From Amsterdam to Rotterdam, Dutch entrepreneurs are building companies that not only disrupt industries but also build personal fortunes that are nothing short of amazing.Each year, Quote magazine unveils its highly anticipated list of the Top 100 Young Self-Made Millionaires, and the 2025 edition confirms that tech remains dominant.These aren’t just early successes; these are founders building serious empires, ranging from remote work infrastructure to AI, design tools, and even crypto platforms.In this article, we have listed the 15 self-made tech millionaires from the above-mentioned list. Do have a look. Job Van Der VoortPosition: CEONet worth: €650M (8.3% increase from 2024)Remote is a global HR platform that helps companies hire, manage, and pay their entire team globally distributed workforces compliantly. With €650M to his name, and an 8.3 per cent increase from last year, Job credits the rise to solid growth “More margin, more customers, and more products — we’re almost profitable.”Job is the CEO and co-founder of Remote. He was previously a neuroscientist before becoming VP of Product at GitLab, the world’s largest all-remote company. With GitLab, he hired talent from 67 countries. Job is a sought-after presenter and often speaks about scaling a remote-first startup, remote culture, and the future of work.Douwe KielaPosition: CEONet worth: €200M (New to list)Contextual AI specialises in retrieval-augmented generation (RAG). The company’s goal is to improve how people work using artificial intelligence (AI)